Skip to content

Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths

Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06217783
Enrollment
400
Registered
2024-01-22
Start date
2024-03-27
Completion date
2027-12-01
Last updated
2026-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oncologic Complications and Emergencies

Brief summary

To learn about the effects of the length of the catheter on the failure and success rate of USIV placement.

Detailed description

Primary Objectives: \- The rate of catheter failure, defined as removal of the catheter for any reason other than "Care Complete" (i.e. a composite of removal due to "infiltration," "leaking," "catheter damage," "occlusion"), by day 10. Secondary Objectives: 1. Time from catheter placement to removal (i.e. survival or dwell time). 2. Per catheter length rate of failure analysis 3. Rate of repeat catheterization 4. Rate of infection 5. Rate of thrombosis

Interventions

DEVICEIntrocan Safety IV Catheter

Given by IV

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age \> 18 years old. 2. Provision of signed and dated informed consent form. 3. Predetermined to have difficult IV access necessitating USIV placement 4. Expected admission to hospital with anticipated stay \> 48 hours (per discussion with treating physician).

Exclusion criteria

1. Expected/anticipated discharge disposition from the ACCC (per discussion with treating physician). 2. Inability to give informed consent. 3. Pregnant women. 4. Non-English speaking participants.

Design outcomes

Primary

MeasureTime frameDescription
Safety and adverse events (AEs)Through study completion; an average of 1 year.Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

Countries

United States

Contacts

CONTACTJonathan Rowland, MD
jwrowland@mdanderson.org(832) 450-8954
PRINCIPAL_INVESTIGATORJonathan Rowland, MD

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 24, 2026